1. SteriPort Line 3 startup - Commercial production is intended in the last week of August 2026, with FDA inspection scheduled for August 21. Management targets ₹110-120 crore incremental annual revenue at \~27% EBITDA margin, with EBITDA margin expanding by 3-4%.
2. Captive solar power - The 10.8 MW plant at Village: Baroda, Taluka: Matar, District: Kheda has been generating since May 30, 2026, saving roughly ₹9 crore annually. That is \~₹9 crore annual EBITDA improvement on a company that earned ₹59.5 crore EBITDA - a \~15% boost, with a 3.6-year payback.
3. Export market expansion - Export share was 32% of revenue in FY26, with 27 countries served and 47 products registered across 120 jurisdictions. Management is prioritizing advanced and semi-regulated markets, where inhalation and ophthalmic products target higher margins than domestic IV fluids.
4. New dosage forms and packaging - Management is exploring glass packaging, IV bags, injectables, lyophilized products, and cartridges, with clarity expected by December 2025-January 2026. This could extend the sterile-liquids franchise beyond plastic containers into higher-value formats, though it remains exploratory.